Anhui Anke Biotechnology Group Co Ltd

Anhui Anke Biotechnology Group Co Ltd maintains a strong liquidity position, with a current ratio of 3.74, indicating the company can cover its short-term liabilities more than three times over. The company's liquidity_fpt score is high, supported by a free cash flow of 333,664,440 CNY and a net cash position that is negative after subtracting total debt. The debt-to-equity ratio is 0.01, suggesting a conservative capital structure with minimal leverage. The company's profitability is robust, with a return on equity (ROE) of 16.13% and a return on assets (ROA) of 13.25%, both exceeding the industry median for pharmaceutical firms. Gross profit of 1,985,890,110 CNY and operating income of 836,577,970 CNY reflect strong cost control and pricing power. Net income of 735,192,710 CNY demonstrates the company's ability to convert revenue into profit effectively. Geographically, the company's revenue is concentrated in China, with no disclosed international operations. The company operates in a single business segment, focusing on biopharmaceuticals, which accounts for 100% of its revenue. This concentration may expose the company to regulatory and macroeconomic risks specific to the Chinese market. The company's growth trajectory is positive, with revenue of 2,646,519,770 CNY in the latest period. While no forward-looking revenue guidance is provided, the company's operating cash flow of 863,220,470 CNY and free cash flow of 333,664,440 CNY suggest strong cash generation capabilities. Capital expenditures of -126,891,930 CNY indicate a net cash inflow from investing activities, potentially supporting future growth. The company faces moderate liquidity risk, as noted in the risk assessment, with a liquidity score of medium. The risk of dilution is low, with no significant dilution potential identified in the basic shares outstanding. The company's ESG profile is mixed, with a high social pillar score of 9.74 but a low governance pillar score of 26.04. The ESG controversies score is 100.00, indicating no recent controversies. Recent events include the latest actual EPS of 0.44 CNY and revenue of 2,646,520,000 CNY, as reported by analysts. No recent filings or transcripts are available for further insight into the company's strategic direction or operational performance.